Clinical trials: sponsored by AstraZeneca
Capsaicin Evoked Pain, Heat Sensitivity
Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)
A double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked pain symptoms and heat sensitivity in healthy volunteers
- Trial name
- NCT00692146
- Testing
- AZD1386
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Antiplatelet Effect
Study to Investigate Safety and Tolerability of a Single Dose of AZD6482
AZD6482 is a new drug substance aiming to prevent blood clots which may arise in atherosclerotic blood vessels and cause myocardial infarction or stroke. This is the first study with AZD6482 in humans.
- Trial name
- NCT00688714
- Testing
- AZD6482
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
In this study it is intended to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg and the combination of candesartan 32 mg and HCT 12.5…
- Trial name
- NCT00383929
- Testing
- Candesartan cilexetil, Hydrochlorothiazide
- Where
- 132 sites in Denmark, Estonia and 9 more
- Volunteers
- 1,979 people
- Sponsor
- AstraZeneca
Breast Cancer
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.
- Trial name
- Ax-003 (NCT00638391)
- Testing
- Anastrozole
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
GALLANT 7 Tesaglitazar Add-on to Sulphonylurea
This is a 24-week randomized double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 mg and 1 mg) given as add-on therapy to sulphonylurea in patients with type 2 diabetes, not adequately…
- Trial name
- NCT00251940
- Testing
- Tesaglitazar 0.5 or 1 mg, Glibenclamide 2.5, 5, 10 or 15 mg
- Where
- 84 sites in Australia, France and 8 more
- Volunteers
- 555 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
GALLANT 22 Tesaglitazar vs. Placebo
This is a 24-week randomized, double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone…
- Trial name
- NCT00252837
- Testing
- Tesaglitazar, Dietary and Lifestyle counseling
- Where
- 101 sites in Australia, Czechia and 12 more
- Volunteers
- 475 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104…
- Trial name
- NCT00252876
- Testing
- tesaglitazar
- Where
- 277 sites in United States, Argentina and 29 more
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
GALLANT 4 Tesaglitazar vs. Glibenclamide
This is a 52-week randomized, double-blind, parallel-group, multi-center, active-controlled (glibenclamide) study of tesaglitazar in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone…
- Trial name
- NCT00255541
- Testing
- Tesaglitazar, Glibenclamide
- Where
- 66 sites in Belgium, Hong Kong and 11 more
- Volunteers
- 580 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)
This is a long-term safety follow-up study to assess the post-treatment safety, at 12 and 24 months, in patients with type 2 diabetes after participation in the phaseII/III studies GALLANT, GALLEX and ARMOR.
- Trial name
- NCT00255645
- Where
- 543 sites in United States, Argentina and 38 more
- Volunteers
- 4,500 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity
This is a 16-week randomized, double-blind, parallel-group, multi-center, placebo- and active- (metformin 1.5 g) controlled study of tesaglitazar (1 mg) in patients with type 2 diabetes.
- Trial name
- NCT00263965
- Testing
- Tesaglitazar, Metformin, Dietary and lifestyle modification counseling
- Where
- 3 sites in Finland, Italy and 1 more
- Volunteers
- 105 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes
This is a parallel-group, multi-center, long-term extension study from the GALLANT 4 study to monitor the safety and tolerability of oral tesaglitazar compared with glibenclamide in patients with type 2 diabetes for up to 100…
- Trial name
- NCT00300105
- Testing
- Tesaglitazar
- Where
- 42 sites in Belgium, Hong Kong and 8 more
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Gynecomastia
Gynecomastia Extension Study
The purpose of this study is to look at the effect of anastrozole (ZD1033, Arimidex™) in reducing gynecomastia in pubertal boys treated with placebo in Trial 1033US/0006 (another anastrozole study).
- Trial name
- NCT00637182
- Testing
- Anastrozole
- Sponsor
- AstraZeneca
Heartburn, Upper Abdominal Pain
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2…
- Conditions
- Heartburn, Upper Abdominal Pain, Nausea, Acid Regurgitation
- Trial name
- NCT00625274
- Testing
- Esomeprazole, Lansoprazole, Pantoprazole
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
GERD
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency \& severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting…
- Trial name
- NCT00567619
- Where
- Austria
- Volunteers
- 900 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Symbicort in Chronic Obstruktive Pulmonary Disease
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine…
- Trial name
- SYMBIOSE (NCT00612976)
- Volunteers
- 18,014 people
- Sponsor
- AstraZeneca
Gastrointestinal Diseases
Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine…
- Trial name
- NCT00612027
- Volunteers
- 29,586 people
- Sponsor
- AstraZeneca
Gastrointestinal Diseases
Symptoms and Endoscopic Results in Consideration of Pretreatment
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine…
- Trial name
- NCT00612404
- Volunteers
- 16,255 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia
This clinical trial is being performed to investigate the effect of 12 weeks treatment with rosuvastatin and atorvastatin in bringing subjects to their established EAS LDL-C target goal.
- Trial name
- NCT00241488
- Testing
- Rosuvastatin
- Where
- 34 sites in China, Hong Kong and 4 more
- Volunteers
- 1,362 people
- Sponsor
- AstraZeneca
Essential Hypertension, Left Ventricular Hypertrophy
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CandLE (NCT00607633)
- Volunteers
- 686 people
- Sponsor
- AstraZeneca
Essential Hypertension
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CoCa (NCT00608153)
- Volunteers
- 1,773 people
- Sponsor
- AstraZeneca